Vermillion (VRML) +29.4% premarket after the developer of diagnostic tests signs a cooperative...

|By:, SA News Editor

Vermillion (VRML) +29.4% premarket after the developer of diagnostic tests signs a cooperative research and development agreement with the U.S. Army. A two-phase study will investigate the cost-benefit profile of OVA1 testing as a presurgical standard of care in women with pelvic masses, and assess OVA1 clinical utility in a managed care setting.